Hevea Brasiliensis-derived Extracellular Vesicles (HB-EVs) for smart/targeted cancer therapy

• Grant number: 25/12962-9
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2025
• End date: October 31, 2026
• Field of knowledge: Engineering - Biomedical Engineering - Bioengineering
• Mobility Program: SPRINT - Projetos de pesquisa - Mobilidade
• Principal Investigator: Juliana Ferreira Floriano
• Grantee: Juliana Ferreira Floriano
• Principal researcher abroad: Oscar Wiklander
• Institution abroad: Karolinska Institutet , Sweden
• Host Institution: Faculdade de Ciências (FC). Universidade Estadual Paulista (UNESP). Campus de Bauru. Bauru , SP, Brazil
• City of the host institution: Bauru
• Associated researchers: Sergio Pereira
• Associated research grant: 23/12304-6 - Study and Bioengineering of natural rubber latex-derived extracellular vesicles: a novel targeted molecule delivery system with high potential for Regenerative Medicine, AP.JP

Abstract

This international collaborative project between São Paulo State University (UNESP) and Karolinska Institutet (KI-SE) aims to explore Hevea brasiliensis-derived extracellular vesicles (HB-EVs) as a novel, EVs plant-based smart therapy for cancer. Building on UNESP's ongoing FAPESP-funded Young Investigator Award, the project will first characterize the innate anticancer properties of HB-EVs and compare them to mammalian-derived EVs. In a second phase, HB-EVs will be bioengineered with targeting moieties (e.g., monoclonal antibodies) and loaded with therapeutic RNA to increase tumor specificity and efficacy, reducing toxic effects on healthy tissues. The collaboration will integrate UNESP's expertise in biomaterials and regenerative medicine with KI-SE's leadership in EV bioengineering and precision oncology. Through exchange visits, joint workshops, and advanced training, the initiative will generate high-impact data, co-authored publications, and patentable innovations. Ultimately, this partnership seeks to establish HB-EVs as a safe, cost-effective, and cell-free alternative to current cancer therapies, while strengthening international cooperation and translational research capacity in both institutions. (AU)